Switching to investigational once-weekly insulin icodec from other basal insulins
Switching to investigational once-weekly insulin icodec from other basal insulins demonstrated to be efficacious and well-tolerated for people with type 2 diabetes in phase 2 trial. Novo Nordisk announced results …
